Study sheds new light on old drugs for treating trauma

A new study from Australia, New Zealand and Germany New England Journal of Medicine An important question arises as to whether emergency care will be successful.

This study looked at tranexamic acid, a drug commonly used to control bleeding during surgery. However, its usefulness in emergencies as a preemptive strike against life-threatening bleeding is controversial, with recent studies yielding conflicting results as to whether it saves lives or causes dangerous blood clots. It is shown.

The Prehospital Antifibrinolytics for Traumatic Coagulation and Bleeding (PATCH-Trauma) study was designed to resolve this dilemma. Led by Monash University and the Australia and New Zealand Intensive Care Association Clinical Trials Group, the trial is the largest clinical trial ever conducted, involving treatment in roadsides, ambulances and helicopters prior to hospital arrival. one of.

The plan involved 1,310 seriously injured patients treated at 15 ambulance services and 21 trauma centers in Australia, New Zealand and Germany and took eight years to complete.

In addition to all usual care, patients were randomly assigned to receive tranexamic acid or an inactive placebo before admission. They found that for every 100 patients assigned to receive tranexamic acid, approximately 4 extra patients were alive at 6 months, all of whom were severely disabled and highly dependent on their caregivers. was shown.

Lead researcher Professor Russell Gruen, now Dean of the Australian National University School of Health and Medicine, called it a landmark study in wound care. “This shows that it’s not enough just to see if a treatment saves lives. Quality of life and long-term treatment outcomes are also important,” said Professor Gruen.

Professor Stephen Barnard of Monash University, Medical Advisor to Victoria Ambulance and Head of the Australian Division of Research, praised the ambulance services involved. “The PATCH-Trauma Study further proves that ambulance professionals are capable of conducting rigorous clinical trials in critically ill patients and under extremely difficult circumstances,” he said.

Professor Gruen is cautious about whether tranexamic acid should be used in trauma patients. “Because this drug should be administered before critically injured patients can make informed decisions, it is important that patients who are likely to maintain a good functional outcome and survive if they receive tranexamic acid are more likely to survive.” We need more research to see if we can identify it,” he said. . “But the PATCH-Trauma Study gives us confidence that critical care is possible long before patients reach the hospital.”


About Monash University

Monash University is Australia’s largest university with over 80,000 students. Over the past 60 years, we have built a reputation for world-leading and influential research, quality education, and inspiring innovation.

With four campuses in Australia and also campuses in Malaysia, China, India, Indonesia and Italy, it is one of Australia’s most international universities.

As a leading international medical research university with Australia’s largest medical school and integration with Australia’s leading teaching hospitals, we are consistently ranked among the world’s top 50 universities in clinical, preclinical and health sciences.

For more news, visit Medicine, Nursing, Health Sciences, or Monash University.

Media inquiries

E: media@monash.edu

#Study #sheds #light #drugs #treating #trauma

Be the first to comment

Leave a Reply

Your email address will not be published.


*